Fulvestrant + Abemaciclib
The combination of abemaciclib and fulvestrant shows promising efficacy and manageable toxicity in HR-positive advanced or recurrent endometrial cancer, especially in CN-L/NSMP tumors
Shitanshu Uppal
GYOEDU Podcast
Spotify Link
Website Link
GYOEDU: Interview PodcastSeason 1GYOEDU PlusShitanshu Uppal
Publications Update # 83
A trick to powerful speaking, LEAP-001 Study: Pembro/Lenvima vs. Carbo/Taxol in EndoCa, Opportunistic Salpingectomy.
LEAP-001: Pembro/Lenvima vs. Carbo/Taxol in Advanced/Recurrent Endometrial Cancer
First-line lenvatinib plus pembrolizumab did not significantly improve PFS or OS compared to chemotherapy in mismatch repair-proficient (pMMR) advanced endometrial cancer. Toxicity was higher in the experimental arm but manageable.
dMMR exploratory analysis shows promise in this subgroup.
Anticoagulation and Bleeding
Chemotherapy Infusion Emergencies
Publications Update # 82
Book recommendation - Get It Done by Ayelet Fishbach, MITO-18 trial summary and discussion points, NEJM paper - BALANCE trial, Trial flashback - road to carboplatin and taxol video (5 mins)
GYOEDU Resident: Non-Epithelial Tumors of the Ovary
Hi there,
This video is a part of the GYOEDU
CHIPOR Trial: Secondary Debulking and HIPEC in Platinum Sensitive Recurrence
HIPEC combined with cytoreductive surgery significantly improved overall survival and progression-free survival in recurrent ovarian cancer
Publications Update # 81
Video summary of CHIPOR trial, study summary of CHIPOR trial